Skip to main content

Wendell Jones, Samraat Raha, Jim Slater, Mark Chandler, Walter Loewenbaum, Thomas Erickson, Mickey Urdea, Elena Grigorenko


Wendell Jones has joined Expression Analysis of Research Triangle Park, N.C., as a senior research statistician. Jones, who holds a PhD in mathematical sciences from Clemson University, previously worked for IBM as a senior software reliability engineer and as a manager of research and technology at Nortel Networks.

Samraat Raha has become chief business officer of Madison, Wis.-based EraGen. He joins the company from Incyte Genomics, where he was vice president of discovery services, including microarrays and bioreagents. Raha received a BA in molecular and cell biology from the University of California at Berkeley.

Jim Slater, executive chairman of investment company BioProjects International, has joined ViaLogy’s board of directors. BioProject International has been the lead investor of ViaLogy’s recent series A round. ViaLogy, a portfolio company of Viaspace Technologies, is developing technology to increase the detection sensitivity of DNA microarrays and other platforms.

Mark Chandler is planning to resign as president and CEO of Luminex in order to become chairman and CEO of a spinout the company is hoping to form of its Rules-Based Medicine unit (see story on page 1). While Chandler would remain a director of Luminex, Walter Loewenbaum would succeed him as chairman of the board of directors, and Thomas Erickson would join Luminex as interim president and CEO.

Mickey Urdea has been appointed to the board of directors of Quantum Dot, based in Hayward, Calif. Urdea is a founder of Chiron and a former senior vice president of nucleic acid diagnostics at Bayer. At Chiron, he developed branched DNA hybridization assays. After leaving Bayer, Urdea, who holds a PhD in biochemistry from Washington State University, became a biotechnology consultant for sev-eral firms.

Elena Grigorenko has joined the advisory board of NuGEN of San Carlos, Calif. She has been a researcher at Millennium Pharmaceuticals since 2000, where she has been responsible for projects that include microarray platform evaluations and RNA labeling improvements. Prior to that, Grigorenko was an instructor and assistant professor at the Wake Forest University school of medicine where she directed the molecular biology/microarray core facility. She holds a PhD in biochemistry from the Institute of Biological Physics of the Russian Academy of Sciences.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.